

Clinical presentation of spasticity and passive range of motion deviations in dyskinetic cerebral palsy in relation to dystonia, choreoathetosis, and functional classification systems

Objectives: To map the presence, severity, and distribution of spasticity and passive range of motion (pROM) deviations in dyskinetic cerebral palsy (DCP), and to explore their relation with dystonia, choreoathetosis, and functional abilities.

Methods: This cross-sectional study included 53 participants with DCP. Spasticity was assessed with the Modified Ashworth Scale, limited- and increased pROM (hypermobility) with a goniometer, dystonia and choreoathetosis with the Dyskinesia Impairment Scale, gross motor and manual abilities with corresponding functional classification systems.

Results: Spasticity and limited pROM were correlated with dystonia of the upper limbs ($0.41 < r_s < 0.47$, $< 0.001 < p < 0.002$) and lower limbs ($0.31 < r_s < 0.41$, $0.002 < p < 0.025$), and both functional systems of gross motor ($0.32 < r_s < 0.51$, $< 0.001 < p < 0.018$) and fine manual abilities ($0.34 < r_s < 0.44$, $0.001 < p < 0.014$). Hypermobility is correlated only with choreoathetosis of the lower limbs (0.44 , $p = 0.001$).

Conclusions: Coexisting spasticity and pROM deviations in DCP are functionally limiting and should be addressed accordingly. Hypermobility may lead to an increased luxation risk.

Keywords: cerebral palsy, spasticity, dystonia, choreoathetosis, passive range of motion, functional classification system

1 **Introduction**

2 Cerebral palsy (CP) comprises a group of developmental disorders of movement and posture,
3 classified based on the dominant movement disorder such as spasticity, dystonia,
4 choreoathetosis, and ataxia.¹ Accompanying impairments, including later-developing
5 musculoskeletal problems, non-motor neurodevelopmental problems and/or sensory problems
6 are often present.¹

7 Dyskinetic CP (DCP) is the second most common type of CP after spastic forms with a
8 prevalence up to 15%.² DCP is defined by abnormal postures or movements due to impaired
9 muscle tone regulation and impaired movement control and coordination.² In DCP, dystonia
10 and choreoathetosis are the dominant movement disorders, often simultaneously present.²
11 Dystonia is characterized by involuntary movements and abnormal postures due to sustained
12 muscle contractions, whereas choreoathetosis is characterized by rapid, continuously changing
13 hyperkinetic movements.²⁻⁴ The severity of dystonia is higher than the severity of
14 choreoathetosis with larger negative impact on functional motor abilities.^{5,6} As a result,
15 treatment options are strongly focused on dystonia as its impact on daily life activities, societal
16 participation, and quality of life is larger.⁷

17 Beside the predominant dystonia and choreoathetosis, the coexistence of spasticity as a
18 concurrent hypertonia component (i.e. mixed hypertonia) in DCP is often observed.⁸⁻¹⁰
19 Previous studies report high percentages of coexisting spasticity, such as 61% and 71% of the
20 participants with DCP.^{11,12} This is clinically relevant as different movement disorders like
21 spasticity and dystonia require a different treatment management, thus unidentified coexisting
22 movement disorders may impact the success of an outcome following an intervention.⁸⁻¹⁰ For
23 instance, in spastic CP, a selective dorsal rhizotomy or tendon transfer surgery may result
24 unsuccessful due to unrecognized coexistence of dystonia.^{8,13,14} In DCP, the implications that

25 spasticity may have as a coexisting movement disorder are not fully explored, but it is likely to
26 impact clinical outcomes if left unidentified and untreated. Previous research does not report
27 the severity and the distribution of spasticity in different body regions in the DCP population.
28 This knowledge gap makes the management of DCP even more challenging.

29 Apart from the coexisting movement disorders, CP is often characterized by accompanying
30 musculoskeletal abnormalities resulting from the combination of muscle weakness and
31 hypertonia.¹⁵ Individuals with DCP are at high risk of developing musculoskeletal deformities
32 and their clinical implications are only scarcely investigated.¹⁶ Passive range of motion
33 (pROM) is widely used to inform clinical decisions on the therapeutic management of CP,
34 especially important in preventing the development of contractures.¹⁷ pROM of individuals
35 with CP is lower than their typically developing peers, further decreasing with an increase in
36 age and functional limitations.¹⁶⁻¹⁹ The number of participants with DCP included in these
37 studies is low compared to spastic CP, thus conclusions cannot be inferred merely for the DCP
38 population. In addition, clinical practice shows that beside limited pROM, joint hypermobility
39 (i.e. increased pROM)²⁰ is present in individuals with DCP, often linked to increased luxation
40 risk and pain. To the best of researchers' knowledge, joint hypermobility has not been
41 described before in individuals with DCP.

42 Identifying all coexisting movement disorders and impairments during assessment of patients
43 with DCP may thereby hold important clinical information which would assist tailoring an
44 appropriate management strategy leading to improved clinical outcomes.^{2,8-10,12,13}

45 Therefore, this retrospective study aims to increase insights in the clinical presentation of
46 spasticity and pROM deviations in individuals with DCP, and to assess the relationships of
47 spasticity and pROM deviations with dystonia, choreoathetosis, and functional motor abilities.

48 **Materials and Methods**

49 ***Participants***

50 In this retrospective cross-sectional study, participants, aged 6 to 22 years were recruited from
51 five Flemish special education schools for motor disabilities. Inclusion criteria were (1)
52 diagnosed with DCP by a paediatric neurologist and (2) a good ability to understand and follow
53 instructions. Exclusion criteria were (1) change in medication within the previous 3 months
54 and (2) orthopaedic or neurosurgical interventions within the previous 12 months. Ethical
55 approval was obtained from the Medical Ethics Committee UZ KU Leuven. Assent to
56 participate was obtained by all participants and informed consent forms were signed by them
57 or their parents.

58 ***Assessment and procedure***

59 Clinical examinations to assess the presence and severity of spasticity, pROM, dystonia, and
60 choreoathetosis were administered by an experienced physiotherapist at the special education
61 schools of the participants. Spasticity and pROM deviations were each measured twice on the
62 same occasion, and the score representing the higher impairment was used for further analyses.
63 Functional motor abilities (i.e. gross motor and manual abilities) were evaluated the same day
64 as the other clinical examinations.

65 Spasticity was measured using the Modified Ashworth Scale (MAS).²¹ The MAS describes the
66 resistance of a muscle during a passive stretch on a six-point ordinal scale (scores 0, 1, 1.5, 2,
67 3, and 4 where a score of 0 is assigned if the muscle tone is normal, and a score of 4 is assigned
68 if no motion is possible due to rigidity). The MAS in the current study was measured in 22
69 muscle groups, that is, 11 muscle groups in each side of the body. In the upper limbs (UL),
70 spasticity was measured for the elbow flexors and extensors, for the forearm supinators and
71 pronators, and for the wrist dorsiflexors and palmarflexors. In the lower limbs (LL), spasticity

72 was measured for the hip abductors (0 and 90 degrees), for the hamstrings, for the soleus, and
73 for the gastrocnemius.

74 pROM was determined using goniometric measurements^{22,23} following a standardized protocol
75 used in the Movement Lab of the University Hospital Leuven. pROM in the current study was
76 calculated in 38 joint movements, that is, 19 joint movements in each side of the body. In the
77 UL, pROM was measured in a supine position for the shoulder (flexion, extension, abduction,
78 adduction) and for the elbow (extension, flexion), and in a supine position with a 90° elbow
79 flexion for the wrist (dorsiflexion, palmar flexion). In the LL, pROM was measured in a supine
80 position for hip flexion (Thomas test), in a supine position with extended knees for hip
81 abduction and hip adduction, in a supine position with flexed knees for hip external- and
82 internal rotation, and in a prone position for hip extension. Knee flexion and knee extension
83 were assessed in a supine position. Ankle dorsiflexion was assessed using the Silfverskiöld
84 test²⁴ with knees both flexed and extended to differentiate between gastrocnemius and soleus
85 muscle contraction. Ankle plantarflexion was measured in a supine position with knees flexed.
86 Presence and severity of dystonia and choreoathetosis were assessed using the Dyskinesia
87 Impairment Scale (DIS).²⁵ The DIS has a subscale for dystonia (DIS-D) and choreoathetosis
88 (DIS-CA), measuring duration (i.e. the amount of time that dystonia and choreoathetosis were
89 present, range 0-4) and amplitude (i.e. the range of motion in which dystonia and
90 choreoathetosis are present, range 0-4). In the current study, the DIS was assessed in the UL
91 (proximal and distal) and the LL (proximal and distal).

92 The Gross Motor Function Classification System (GMFCS)^{26,27} and the Manual Ability
93 Classification System (MACS)^{27,28} were used to assess the gross motor and fine manual
94 abilities of the participants.

95 ***Outcome measures***

96 Presence of spasticity was calculated by dichotomizing the MAS data per muscle group.^{29,30} A
97 0-score was assigned when spasticity was absent in a muscle group (MAS score = 0) and a 1-
98 score when there was a sign of spasticity present (MAS score = 1, 1.5, 2, 3, 4). Presence of
99 spasticity for the whole body, for the UL, and the LL was calculated by summing the
100 dichotomised scores per participant per muscle group, accounting for both the right and left
101 side of the body. This leads to a possible summed score from 0-22 for the whole body, 0-12
102 for the UL (0-4 for the UL proximal, 0-8 for the UL distal), and 0-10 for the LL (0-6 for the
103 LL proximal and 0-4 for the LL distal). The summed score was converted into a percentage
104 relative to the maximum score per body segment. A median percentage score and an
105 interquartile range was then calculated for the sample. Additionally, presence of spasticity for
106 each measured muscle group was calculated among the sample. This has been done by scoring
107 each measured muscle group of every participant from 0-2 (0 = no spasticity, 1 = spasticity
108 only present in left or right side of body, 2 = spasticity present in both sides of the body), and
109 subsequently summing the scores of all participants for that particular muscle group. This
110 summed score was then converted into a percentage relative to the maximum possible score
111 (Maximum possible score is 106, namely, 53 (participants) * 2 (score if presence in both left
112 and right side of body)).

113 Severity of spasticity per body segment was calculated by summing the MAS scores (0, 1, 1.5,
114 2, 3, 4) of all measured muscle groups per participant (22 muscle groups),^{31,32} and converting
115 this score into a percentage relative to the maximum possible score of a body segment, i.e. 48
116 for the UL (16 for the UL proximal and 32 for the UL distal), and 40 for the LL (24 for the LL
117 proximal and 16 for the LL distal). A median percentage score and an interquartile range was
118 then calculated for the sample. Severity of spasticity for each muscle group was calculated
119 among the sample by summing the MAS scores of all participants for the left and right side of
120 each muscle group. This summed score was then converted into a percentage relative to the

121 maximum score of 424, that is, 53 (participants) * 2 (body sides) * 4 (maximum possible MAS
122 score) = 424. The mode of spasticity severity aimed to inform which MAS score reoccurred
123 most often in each muscle group, and it was calculated excluding the 0 scores (i.e. including
124 only MAS scores 1, 1.5, 2, 3, and 4).

125 pROM was calculated for both limited pROM (pROM-) and increased pROM (pROM+ i.e.
126 joint hypermobility) relative to the normal ROM. First, the measured ROM per participant for
127 each joint movement was subtracted from the respective normal ROM, and the obtained value
128 was either negative (indicating pROM-) or positive (indicating pROM+). For instance, for
129 ankle dorsiflexion where 20° is considered as normal ROM, the calculation would be as
130 follows: 10° (measured pROM) – 20° (normal ROM) = -10° (indicating pROM-); or 50°
131 (measured pROM) – 20° (normal ROM) = 30° (indicating pROM+). Second, a 25th (first
132 quartile Q1) and 75th (third quartile Q3) percentile was calculated separately for the negative
133 values (i.e. pROM-) and for the positive values (i.e. pROM+).³² All pROM measurements were
134 transformed to a 3-point ordinal scale ranging from 0 to 2, using their 25th and 75th percentile
135 as cut-off values. As such, for pROM-, 0 was assigned for values higher than the 75th percentile,
136 indicating no or slight limited pROM; 1 was assigned for values between the 25th and the 75th
137 percentile, indicating moderately limited pROM; and 2 was assigned for values lower than the
138 25th percentile, indicating severely limited pROM. For pROM+, 0 was assigned for values
139 lower than the 25th percentile, indicating no or slight increase in pROM; 1 was assigned for
140 values between the 25th and the 75th percentile, indicating moderately increased pROM; and 2
141 was assigned for values higher than the 75th percentile, indicating severely increased pROM.
142 These assigned ordinal scores were summed up for pROM+ and pROM- separately, and
143 converted into a percentage score relative to the maximum possible score, i.e. maximum
144 possible score of 36 for the UL (28 for the UL proximal and 8 for the UL distal), and 40 for the
145 LL (32 for the LL proximal and 8 for the LL distal). A median percentage score and an

146 interquartile range was then calculated for the sample. Additionally, pROM- and pROM+ for
147 each joint movement separately were calculated among the sample by summing the ordinal
148 scores of all participants for each joint movement, and converting the summed score into a
149 percentage relative to the maximum possible score of 212, that is, 53 (participants) * 2 (body
150 sides) * 2 (maximum possible pROM score) = 212.

151 Dystonia and choreoathetosis scores were transformed into percentage scores relevant to their
152 maximum score (maximum possible score of 288 for each subscale). A median percentage
153 score and an interquartile range was calculated for the sample.

154 *Statistical Analyses*

155 The Shapiro-Wilk test showed that most data were not normally distributed, therefore non-
156 parametric statistics were applied. Descriptive statistics were used to describe presence,
157 severity, and distribution of spasticity, pROM deviations, dystonia, and choreoathetosis across
158 body regions. The Wilcoxon-Signed Rank test was used for statistical comparisons of
159 spasticity, pROM deviations, dystonia, and choreoathetosis (both between and within body
160 regions).³³ Spearman's rank correlation coefficients (r_s) were used to explore the correlations
161 between spasticity, pROM deviations, dystonia, choreoathetosis, and the functional
162 classification scales (i.e. LL values for all parameters were correlated with the GMFCS whereas
163 UL values for all parameters were correlated with the MACS). Correlation coefficients of <0.25
164 were considered as weak or no association, 0.25–0.50 as fair, 0.50–0.75 as moderate to good
165 and >0.75 as excellent.⁵ Statistical significance was set at $p < 0.05$. Data was analysed using
166 IBM SPSS Statistics v26 (SPSS Inc., Chicago, IL).

167 **Results**

168 *Participants*

169 Fifty-three participants (29 male), aged 6 to 22 years (mean age 15y 7mo, SD 4y 4mo) were
170 included in this study. Ten participants were classified as GMFCS level I, five as level II, five
171 as level III, seven as level IV and 26 as level V. Eight participants were classified as MACS
172 level I, five as level II, six as level III, ten as level IV and 24 as level V. Signs of coexisting
173 spasticity, pROM-, and pROM+ in at least one body region were present in 50 (94,3% of the
174 sample), 52 (98,1% of the sample) and 53 participants (100% of the sample), respectively.

175 ***MAS presence and severity, pROM deviations, dystonia, and choreoathetosis***

176 Median percentage values, statistical comparisons, and correlations of the MAS presence and
177 severity, pROM deviations, dystonia, and choreoathetosis between body regions are presented
178 in Table 1. The distribution across body regions is presented in Table 2 (absolute values and
179 percentage values of MAS presence; absolute values, percentage values, and mode of MAS
180 severity) and Table 3 (pROM- and pROM+).

181 *Median percentage scores for the UL and the LL*

182 The median percentage score of MAS presence for the UL was 16.7% (IQR 8.3–41.7%) and
183 ranged between 0.0% and 75.0% of the maximum score, and for the LL was 50.0% (IQR 30.0-
184 80.0%) ranging between 0.0% and 100% of the maximum score. The median percentage score
185 of MAS severity for the UL was 6.3% (IQR 2.1-13.5%; range 0.0% and 30,2% of the maximum
186 score) and for the LL was 18.8% (IQR 8.8-30.0%; range between 0.0% and 95.0%).

187 For pROM- deviations, the median percentage score for the UL was 8.3% (IQR 2.8-16.7%;
188 range between 0.0% and 38.9% of the maximum score) and for the LL was 27.5% (IQR 15.0-
189 35.0%; range between 0.0% and 62.5% of the maximum score). For pROM+ deviations, the
190 median percentage score for the UL was 30.6% (IQR 22.2-36.1%; range between 2.8% and
191 55.6% of the maximum score) and for the LL was 17.5% (IQR 10.0-22.5%; range between
192 0.0% and 42.5%).

193 The median percentage score of dystonia for the UL was 83.3% (IQR 62.5–94.8%; range
194 between 0.0%.9% and 100.% of the maximum score) and for the LL was 78.1% (IQR 52.1-
195 87.5%; range between 21.9% and 100% of the maximum score). The median percentage score
196 of choreoathetosis for the UL was 28.1% (IQR 14.6-53.1%; range between 0.0% and 89.6% of
197 the maximum score) and for the LL was 18.8% (IQR 8.8-41.3%; range between 0.0% and
198 68.8% of the maximum score).

199 *Distribution of MAS presence and severity, and pROM deviations across body regions*

200 A high MAS presence was found in the plantar flexion muscles, that is, from the total 106
201 separate muscles (i.e. 53 participants * 2 body parts), 67 (63.2%) of total m.soleus and 75
202 (70.8%) of total m.gastrocnemius showed signs of spasticity presence. The lowest MAS
203 presence was obtained in the forearm pronators with 6/106 (5.7%) and wrist palmarflexors with
204 5/106 (4.7%). MAS severity was higher in the plantar flexion muscles with a score of 110
205 (25.9%) and 136.5 (32.2%) out of the maximum severity score (i.e. 424) for m.soleus and
206 m.gastrocnemius respectively, and lower in the palmar flexion muscles with a score of 4/424
207 (1.7%).

208 pROM- was more present and severe for knee extension (48.1% of the maximum score) in the
209 LL, and shoulder internal rotation (35.8% of the maximum score) for the UL. On the other
210 hand, pROM+ was more present and severe for hip internal rotation for the LL and shoulder
211 external rotation for the UL with 44.8% and 47.2% of the maximum score respectively.

212 *Statistical comparisons and correlations between and within body regions*

213 Statistical comparisons revealed significantly higher levels of MAS presence, MAS severity,
214 and pROM- in the LL compared to the UL with $p < 0.001$. On the other hand, pROM+
215 ($p < 0.001$), dystonia ($p = 0.014$), and choreoathetosis ($p < 0.001$) showed significantly higher
216 levels in the UL compared to the LL. MAS presence and MAS severity were significantly

217 higher in the UL proximal ($p=0.001$ and $p=0.002$ respectively), and in the LL distal ($p<0.001$)
218 compared to their counterparts. pROM- was significantly higher in the UL proximal ($p<0.001$)
219 and LL proximal ($p=0.004$), whereas pROM+ was significantly higher in the UL distal
220 ($p<0.001$) and in the LL distal with a difference not statistically significant ($p=0.082$). Dystonia
221 was significantly higher in UL distal ($p<0.001$) and in the LL distal ($p<0.001$) whereas
222 choreoathetosis levels showed no significant difference between proximal and distal parts of
223 the UL nor LL.

224 The UL and the LL were significantly correlated for MAS presence, MAS severity, pROM-,
225 pROM+, dystonia and choreoathetosis, with correlation coefficients ranging between
226 $0.34<r_s<0.68$, ($p<0.001$ to $p=0.013$). Statistically significant correlations were also found
227 between the UL proximal and UL distal for MAS presence, MAS severity, pROM-, dystonia,
228 and choreoathetosis with correlation coefficients ranging between $0.32<r_s<0.76$
229 ($0.018<p<0.001$), as well as between LL proximal and LL distal for MAS presence, MAS
230 severity, pROM-, pROM+, dystonia, and choreoathetosis ($0.32<r_s<0.63$, $0.020<p<0.001$).

231 ***MAS presence and severity, and pROM deviations related to dystonia and choreoathetosis***

232 Correlation coefficients with 95% CIs and p-values of dystonia and choreoathetosis with
233 presence of spasticity, severity of spasticity, and pROM deviations are presented in Table 4.

234 Total UL DIS-D showed fair and statistically significant correlations with the total UL MAS
235 presence ($r_s=0.41$, 95% CI 0.16–0.61; $p=0.002$), the total UL MAS severity ($r_s=0.44$, 95% CI
236 0.19–0.63; $p=0.001$), and the total UL pROM- ($r_s=0.47$, 95% CI 0.23–0.66; $p<0.001$). Total
237 LL DIS-D showed fair and statistically significant correlations with the total LL MAS presence
238 ($r_s=0.33$, 95% CI 0.07–0.55; $p=0.016$), with the total LL MAS severity ($r_s=0.41$, 95% CI 0.16–
239 0.61; $p=0.002$), and the total LL pROM- ($r_s=0.31$, 95% CI 0.04–0.54; $p=0.025$).

240 Total UL DIS-CA showed no statistically significant correlations with the total UL MAS
241 presence, total UL MAS severity or total UL pROM deviations. Total LL DIS-CA showed fair

242 and statistically significant correlations only with the total LL pROM+ ($r_s=0.44$, 95% CI 0.19–
243 0.63; $p=0.001$).

244 ***MAS presence and severity, pROM deviations, dystonia and choreoathetosis related to the***
245 ***GMFCS and the MACS***

246 Correlation coefficients with 95% CIs and p-values of MAS presence and severity, pROM
247 deviations, dystonia and choreoathetosis with the GMFCS and the MACS are presented in
248 Table 5.

249 The GMFCS showed a fair and statistically significant correlation with both the MAS presence
250 score ($r_s=0.32$; 95% CI 0.06–0.54; $p=0.018$) and the MAS severity score ($r_s=0.42$; 95% CI
251 0.17–0.62; $p=0.002$) whereas moderate to good and statistically significant correlation was
252 obtained with the pROM- ($r_s=0.51$; 95% CI 0.28-0.69; $p<0.001$) and DIS-D ($r_s=0.65$; 95% CI
253 0.46-0.78; $p<0.001$).

254 The MACS showed fair and statistically significant correlations with the MAS presence score
255 ($r_s=0.40$; 95% CI 0.15–0.60; $p=0.003$), the MAS severity score ($r_s=0.44$; 95% CI 0.19–0.63;
256 $p=0.001$), the pROM- ($r_s=0.34$; 95% CI 0.08–0.56; $p=0.014$), and DIS-CA ($r_s=0.31$; 95% CI
257 0.04–0.54; $p=0.027$). The MACS showed excellent and statistically significant correlation with
258 the DIS-D ($r_s=0.78$; 95% CI 0.65–0.87; $p<0.001$).

259 **Discussion**

260 The overall aim of this study was to increase insights in the presence, severity, and distribution
261 of spasticity and pROM deviations in individuals with DCP, and to assess their relationship
262 with dystonia, choreoathetosis, and functional classification scales.

263 The current study is the first to differentiate between the presence and severity of the coexisting
264 signs of spasticity in children with DCP. Obtained median percentage values for the UL and
265 the LL show a higher presence of spasticity compared to its severity, which spasticity severity

266 is clearly lower than the severity of dystonia and choreoathetosis (except for the distal LL).
267 Overall, these results are not unexpected given that a DCP diagnosis is assigned when dystonia
268 and choreoathetosis are the dominant movement disorders,¹ however, notable for not being
269 previously reported. 94.3% of the included participants showed signs of spasticity in at least
270 one muscle group. A population-based study and a more recent cross-sectional study stated that
271 69% and 71% of individuals with DCP show signs of coexisting spasticity, respectively.^{11,12}
272 These studies do not report the muscle groups that were included in measuring coexisting
273 spasticity in DCP, thus making it difficult to compare results with the current study. Higher
274 presence and severity of spasticity were obtained for the LL whereas dystonia and
275 choreoathetosis were more present and severe in the UL, which aligns with previous
276 research.^{11,34} Interestingly, spasticity and limited pROM showed fair and significant
277 correlations with dystonia for the proximal LL but not for the distal LL (where the highest
278 spasticity severity occurs). Correlation coefficients are greater if there is more variability
279 among the observations.³⁵ The interquartile range in the current study shows a lower variability
280 among the observations in the distal LL compared to the proximal LL, especially noticeable
281 for dystonia. The lower variability in dystonia values may thereby explain the lack of
282 significant correlations with spasticity and limited pROM of the distal LL. Nevertheless, the
283 current study is an added value to the body of literature as it extensively describes the
284 distribution of coexisting spasticity across body regions in DCP. This is of importance because
285 managing strategies in CP differ among the various movement disorders and their
286 characteristics.⁸ For instance, botulinum toxin type A (BoNT-A) and intrathecal baclofen show
287 promising results in reducing spasticity, dystonia, and in increasing ROM in DCP.^{2,36-38} On the
288 other hand, specific treatments like selective dorsal rhizotomy would reduce spasticity but have
289 no impact on reducing dystonia^{8,14,37}, whereas deep brain stimulation is most efficient in
290 individuals who have prominent dystonia and none to minimal presence of spasticity.³⁹

291 The current study found fair and significant correlations for spasticity and moderate to
292 good/excellent and significant correlations for dystonia when correlated to the GMFCS and the
293 MACS levels. This may indicate that spasticity has a negative impact on the functional abilities,
294 but perhaps to a lesser extent than dystonia.⁶ Previous research suggests that the severity of
295 dystonia may be such that any features of coexisting spasticity may be overlooked.⁸ When
296 treatment focuses on reducing severe dystonia, an adverse effect could include worsening of
297 choreoathetosis, which indicates that dystonia may prevent the full expression of
298 choreoathetosis.² Thus similarly, it may be that if treatment focuses on reducing severe dystonia
299 while coexisting spasticity is left untreated, spasticity may surface and have a larger negative
300 impact on function. The obtained insights in the current study on the presence, severity, and
301 the distribution of dystonia, choreoathetosis, spasticity, and pROM deviations in DCP are
302 clinically important to inform treatment management and ensure better clinical outcomes.
303 Future research exploring more in-depth the clinical implications of this coexistence are
304 recommended.

305 This is the first study to map pROM deviations of upper and lower limbs in participants with
306 DCP during 38 joint movements, and particularly novel in differentiating between limited- and
307 increased pROM. The hypertonic components of dystonia and spasticity combined with limited
308 pROM lead to fixed musculoskeletal deformities (FMDs)¹⁶ which are often associated with
309 pain and impaired functioning in children and adolescents with DCP.⁴⁰ In the current study,
310 this is supported by the fair significant correlations of dystonia with spasticity and limited
311 pROM but not with hypermobility, likely explained by the hypertonic characteristics of both
312 dystonia and spasticity.³ A previous study reported a high occurrence of FMDs in DCP
313 (accounting for 58% of the included CP cohort), particularly characteristic in DCP cases with
314 mixed hypertonia.¹⁶ FMD onset in DCP cases where spasticity coexists occurs typically around
315 the age of four, which is significantly earlier than in pure DCP cases with an FMD onset at age

316 of nine.¹⁶ The FMDs were not explored in the current study, however, the obtained high
317 percentage of coexisting spasticity and pROM deviations strengthens the claim that individuals
318 with DCP are highly prone to develop FMDs. Given their link with pain and impaired
319 functioning, these additional insights on the distribution of limited pROM across body regions
320 might assist clinical practice with a preventive treatment to maintain normal ROM and
321 symmetric postures at the earliest age possible. For instance, the current study found a higher
322 percentage of limited pROM for hip adduction, hip external rotation, and hip flexion. Previous
323 studies also report a higher presence of musculoskeletal deformities in the hip region compared
324 to other body regions in patients with DCP.¹⁶ Moreover, a population-based study also reported
325 that children with spastic CP show lower ROM for hip adduction, hip external rotation, and hip
326 flexion when compared to typically-developing children.¹⁷ Thus, it may be plausible that the
327 hip limited pROM obtained in the current study is due to the coexistence of spasticity which
328 causes limited pROM in the hip region in people with DCP. Structural changes happen in the
329 hips due to imbalances between flexor/extensor and adductor/abductor muscles, and because
330 of decreased muscle extension and decreased joint ROM.⁴¹ Painful hip dislocation is a common
331 occurrence in CP, the incidence of which can be up to 80% of CP cases and is directly related
332 to the severity of the neurological involvement as well as the ambulatory status of the
333 patient.^{40,42-45} Previous study reports an overall intermediate risk for hip dislocations in people
334 with DCP, however, up to 20% were classified in the highest risk group and this incidence was
335 directly related to their GMFCS levels.⁴⁶ Another study reported that the prognosis for hip
336 displacement was the worse in DCP with 24% of the included sample having abnormal hips.⁴⁷
337 In addition, a high percentage of limited pROM in DCP was also found for shoulder internal
338 rotation, which aligns with previous research reporting structural changes at the shoulder level,
339 especially in mixed cases of CP.⁴⁸ The obtained distribution of the limited pROM in DCP is of
340 particular clinical interest given that significant associations were found between limited

341 pROM, the GMFCS, and the MACS. This might mean that treatment should specifically focus
342 on increasing pROM values at the hip and shoulder level in order to improve functional abilities
343 and/or reduce pain in DCP.

344 In the current study, joint hypermobility (i.e. increased pROM) in at least one joint movement
345 was obtained for all participants, with a higher percentage for hip internal rotation, shoulder
346 adduction, and shoulder external rotation. Increased pROM in DCP has not been described
347 before, thus results cannot be compared to existing literature. Nonetheless, the fair significant
348 correlations which were obtained between joint hypermobility and choreoathetosis are worth
349 noting. Previous research reports joint hypermobility alongside hypotonia,⁴⁹ and maybe
350 similarly, the underlying hypotonic and hyperkinetic (i.e. stormy and high amplitude
351 movements) characteristics of choreoathetosis align with increased pROM in DCP.⁴ Clinical
352 practice supports there is a high luxation risk for individuals with DCP. Even though the current
353 study found no significant correlations between joint hypermobility and functional motor
354 abilities (i.e. the GMFCS and the MACS), future research is strongly encouraged to explore
355 more in-depth its clinical implications, especially because in other populations, joint
356 hypermobility has been associated with chronic joint pain, joint subluxations and dislocations,
357 and soft tissue injuries.⁴⁹

358 Although with clinically important findings to be reported, this study warrants some critical
359 reflections. First, the assessments used in the current study are widely used in clinical research,
360 and their reliability and validity has been reported before.⁵⁰⁻⁵² The insights generated from these
361 studies have increased our understanding of spasticity and ROM, but the interpretation of the
362 scales is dependent on the rater's execution, which could lead to subjective conclusions. In
363 response to this, these evaluation methods are often complemented by the use of sensor
364 measurements and wearables like electromyography recordings, 3D motion analysis or inertial
365 measurement units.⁵³ Future research including sensor measurements and wearables may lead

366 to more in-depth insights on the clinical presentation of all movement disorders and
367 impairments in DCP. In addition to their use in clinical research, there is also a need to bridge
368 the implementation of these sensor measurements in clinical practice. Second, based on the
369 International Classification of Functioning, Disability and Health (ICF) model⁵⁴, clinical
370 outcomes should be assessed on levels of body functioning and structure, activity, and
371 participation. The present study reported the associations between coexisting spasticity and
372 pROM deviations with functional abilities such as the gross motor and fine manual abilities
373 (i.e. body functioning and structure level), thus future research is necessary to explore their
374 implications on other domains such as activity and participation. Third, as indicated by the fair
375 positive correlations between coexisting spasticity and limited pROM with functional scales,
376 it might be possible that there is a slight overestimation of their presence and severity in the
377 UL and LL for the whole population due to the higher number of participants with GMFCS
378 and MACS levels V. However, it is expected this effect to be very minimal given the only fair
379 correlations and wide variability within the functional levels. Lastly, discussing the obtained
380 results by comparing them with previous literature is necessary as it places the study in the
381 field of research. However, it is worth highlighting that the differences which exist between
382 the current study and previous relevant studies (differences in methodology including sample
383 size, assessed body regions, recruitment procedures and inclusion criteria among others) make
384 the comparison of the obtained results more difficult and should therefore be considered.

385 **Conclusion**

386 This study aimed to increase insights in the clinical presentation of spasticity and pROM
387 deviations alongside dystonia and choreoathetosis in individuals with DCP and to assess their
388 relationship with dystonia, choreoathetosis and functional abilities. The severity of spasticity
389 is lower than the severity of dystonia and choreoathetosis, thus dystonia and choreoathetosis
390 remain the dominant movement disorders in DCP. Given the obtained correlations with the

391 functional scales, spasticity and limited pROM seem to have functional implications and should
392 be therefore addressed accordingly. Hypermobility, on the other hand, may lead to an increased
393 luxation risk. The obtained insights in the current study on the presence, severity, and the
394 distribution of dystonia, choreoathetosis, spasticity, and pROM deviations in DCP should
395 inform treatment management and ensure better clinical outcomes.

396 **Acknowledgements**

397 We thank all participants and their parents for their willingness to participate in this study. A
398 wholehearted gratitude to the Committee of Flemish Motor Disability Centers (KOMPAS) and
399 clinicians for their time and invaluable help.

400 **Declaration of interest**

401 The authors report no conflicts of interest.

402 **Funding**

403 This research received no specific grant from any funding agency in the public, commercial,
404 or not-for-profit sectors.

405 **References**

- 406 1. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the
407 definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol Suppl.* 2007;109:8-14.
- 408 2. Monbaliu E, Himmelmann K, Lin JP, Ortibus E, Bonouvrie L, Feys H, et al. Clinical presentation
409 and management of dyskinetic cerebral palsy. *Lancet Neurol.* 2017;16(9):741-9.
- 410 3. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of
411 disorders causing hypertonia in childhood. *Pediatrics.* 2003;111(1):e89.
- 412 4. Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW, et al. Definition and
413 classification of hyperkinetic movements in childhood. 2010. p. 1538-49.
- 414 5. Monbaliu E, de Cock P, Ortibus E, Heyrman L, Klingels K, Feys H. Clinical patterns of dystonia
415 and choreoathetosis in participants with dyskinetic cerebral palsy. *Dev Med Child Neurol.*
416 2016;58(2):138-44.
- 417 6. Monbaliu E, De La Pena MG, Ortibus E, Molenaers G, Deklerck J, Feys H. Functional
418 outcomes in children and young people with dyskinetic cerebral palsy. *Dev Med Child Neurol.*
419 2017;59(6):634-40.
- 420 7. Monbaliu E, De Cock P, Mailleux L, Dan B, Feys H. The relationship of dystonia and
421 choreoathetosis with activity, participation and quality of life in children and youth with dyskinetic
422 cerebral palsy. *European journal of paediatric neurology : EJPN : official journal of the European*
423 *Paediatric Neurology Society.* 2017;21(2):327-35.
- 424 8. Rice J, Skuza P, Baker F, Russo R, Fehlings D. Identification and measurement of dystonia in
425 cerebral palsy. *Dev Med Child Neurol.* 2017;59(12):1249-55.
- 426 9. Gordon LM, Keller JL, Stashinko EE, Hoon AH, Bastian AJ. Can Spasticity and Dystonia Be
427 Independently Measured in Cerebral Palsy? *Pediatric Neurology.* 2006;35(6):375-81.
- 428 10. Rice J, Baker F, Russo R. The spectrum of movement disorders in a cerebral palsy population.
429 *Developmental Medicine & Child Neurology.* 2016;58(S5):47-.
- 430 11. Himmelmann K, Hagberg G, Wiklund LM, Eek MN, Uvebrant P. Dyskinetic cerebral palsy: a
431 population-based study of children born between 1991 and 1998. *Dev Med Child Neurol.*
432 2007;49(4):246-51.
- 433 12. Reid SM, Meehan EM, Reddihough DS, Harvey AR. Dyskinetic vs Spastic Cerebral Palsy: A
434 Cross-sectional Study Comparing Functional Profiles, Comorbidities, and Brain Imaging Patterns.
435 *Journal of child neurology.* 2018;33(9):593-600.
- 436 13. Koman L, Smith B, Shilt J. Cerebral palsy. *Lancet*2004. p. 1619-31.
- 437 14. van de Pol L, Vermeulen R, van 't Westende C, van Schie P, Bolster E, van Ouwkerk P, et al.
438 Risk Factors for Dystonia after Selective Dorsal Rhizotomy in Nonwalking Children and Adolescents
439 with Bilateral Spasticity. 2018;49(1):044-50.
- 440 15. Keenan NW, Rodda CJ, Wolfe KR, Roberts KS, Borton KD, Graham KH. The static examination
441 of children and young adults with cerebral palsy in the gait analysis laboratory: technique and
442 observer agreement. *Journal of Pediatric Orthopaedics B.* 2004;13(1):1-8.
- 443 16. Lumsden DE, Gimeno H, Elze M, Tustin K, Kaminska M, Lin JP. Progression to musculoskeletal
444 deformity in childhood dystonia. *European journal of paediatric neurology : EJPN : official journal of*
445 *the European Paediatric Neurology Society.* 2016;20(3):339-45.
- 446 17. McDowell BC, Salazar-Torres JJ, Kerr C, Cosgrove AP. Passive Range of Motion in a
447 Population-Based Sample of Children with Spastic Cerebral Palsy Who Walk. *Physical & Occupational*
448 *Therapy In Pediatrics.* 2012;32(2):139-50.
- 449 18. Hedberg-Graff J, Granstrom F, Arner M, Krumlinde-Sundholm L. Upper-limb contracture
450 development in children with cerebral palsy: a population-based study. *Dev Med Child Neurol.*
451 2019;61(2):204-11.
- 452 19. Nordmark E, Hagglund G, Lauge-Pedersen H, Wagner P, Westbom L. Development of lower
453 limb range of motion from early childhood to adolescence in cerebral palsy: a population-based
454 study. *BMC medicine.* 2009;7:65.

- 455 20. Romeo DM, Velli C, Lucibello S, Ferrantini G, Leo G, Brogna C, et al. Joint Laxity in Preschool
456 Children Born Preterm. *The Journal of Pediatrics*. 2018;197:104-8.
- 457 21. Bohannon RW, Smith MB. Interrater Reliability of a Modified Ashworth Scale of Muscle
458 Spasticity. *Physical Therapy*. 1987;67(2):206-7.
- 459 22. Glanzman A, Swenson A, Kim H. Range of motion measurement in cerebral palsy: a
460 comparison of assessment methods. *Developmental Medicine and Child Neurology*. 2004;46:36.
- 461 23. Mutlu A, Livanelioglu A, Gunel MK. Reliability of goniometric measurements in children with
462 spastic cerebral palsy. *Medical science monitor : international medical journal of experimental and*
463 *clinical research*. 2007;13(7):Cr323-9.
- 464 24. Singh D. Nils Silfverskiöld (1888–1957) and gastrocnemius contracture. *Foot and Ankle*
465 *Surgery*. 2013;19(2):135-8.
- 466 25. Monbaliu E, Ortibus E, De Cat J, Dan B, Heyrman L, Prinzie P, et al. The Dyskinesia
467 Impairment Scale: a new instrument to measure dystonia and choreoathetosis in dyskinetic cerebral
468 palsy. *Dev Med Child Neurol*. 2012;54(3):278-83.
- 469 26. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and
470 reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child*
471 *Neurol*. 1997;39(4):214-23.
- 472 27. Palisano RJ, Avery L, Gorter JW, Galuppi B, McCoy SW. Stability of the Gross Motor Function
473 Classification System, Manual Ability Classification System, and Communication Function
474 Classification System. *Dev Med Child Neurol*. 2018;60(10):1026-32.
- 475 28. Eliasson AC, Krumlinde-Sundholm L, Rösblad B, Beckung E, Arner M, Ohrvall AM, et al. The
476 Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and
477 evidence of validity and reliability. *Dev Med Child Neurol*. 2006;48(7):549-54.
- 478 29. Alhusaini AA, Dean CM, Crosbie J, Shepherd RB, Lewis J. Evaluation of spasticity in children
479 with cerebral palsy using Ashworth and Tardieu Scales compared with laboratory measures. *Journal*
480 *of child neurology*. 2010;25(10):1242-7.
- 481 30. Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the
482 Ashworth Scale is confounded by it. *Clinical rehabilitation*. 2006;20(2):173-82.
- 483 31. Klingels K, Demeyere I, Jaspers E, De Cock P, Molenaers G, Boyd R, et al. Upper limb
484 impairments and their impact on activity measures in children with unilateral cerebral palsy.
485 *European Journal of Paediatric Neurology*. 2012;16(5):475-84.
- 486 32. Papageorgiou E, Simon-Martinez C, Molenaers G, Ortibus E, Van Campenhout A, Desloovere
487 K. Are spasticity, weakness, selectivity, and passive range of motion related to gait deviations in
488 children with spastic cerebral palsy? A statistical parametric mapping study. *PLOS ONE*.
489 2019;14(10):e0223363.
- 490 33. Portney LG, Watkins MP. *Foundations of clinical research: applications to practice*. 3rd ed.,
491 new int. ed. ed: Harlow : Pearson; 2014.
- 492 34. Pons R, Vanezis A, Skouteli H, Papavasiliou A, Tziomaki M, Syrengelas D, et al. Upper Limb
493 Function, Kinematic Analysis, and Dystonia Assessment in Children With Spastic Diplegic Cerebral
494 Palsy and Periventricular Leukomalacia. *Journal of child neurology*. 2017;32(11):936-41.
- 495 35. Goodwin LD, Leech NL. Understanding Correlation: Factors That Affect the Size of r. *The*
496 *Journal of Experimental Education*. 2006;74(3):249-66.
- 497 36. Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum Toxin in the Management of
498 Children with Cerebral Palsy. *Paediatr Drugs*. 2019;21(4):261-81.
- 499 37. Steinbok P. Selective dorsal rhizotomy for spastic cerebral palsy: a review. *Child's Nervous*
500 *System*. 2007;23(9):981-90.
- 501 38. Bonouvrié LA, Becher JG, Vles JSH, Vermeulen RJ, Buizer AI. The Effect of Intrathecal
502 Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial. *Ann Neurol*. 2019;86(1):79-90.
- 503 39. Elia AE, Bagella CF, Ferre F, Zorzi G, Calandrella D, Romito LM. Deep brain stimulation for
504 dystonia due to cerebral palsy: A review. *European journal of paediatric neurology : EJPN : official*
505 *journal of the European Paediatric Neurology Society*. 2018;22(2):308-15.

- 506 40. McKinnon CT, White JH, Morgan PE, Antolovich GC, Clancy CH, Fahey MC, et al. The lived
507 experience of chronic pain and dyskinesia in children and adolescents with cerebral palsy. *BMC*
508 *Pediatrics*. 2020;20(1):125.
- 509 41. Perez-de la Cruz S. Childhood cerebral palsy and the use of positioning systems to control
510 body posture: Current practices. *Neurologia (Barcelona, Spain)*. 2017;32(9):610-5.
- 511 42. Flynn MJ, Miller MF. Management of Hip Disorders in Patients With Cerebral Palsy. *Journal*
512 *of the American Academy of Orthopaedic Surgeons*. 2002;10(3):198-209.
- 513 43. Graham HK. Painful hip dislocation in cerebral palsy. *The Lancet*. 2002;359(9310):907-8.
- 514 44. Presedo A, Oh C-W, Dabney KW, Miller F. Soft-tissue releases to treat spastic hip subluxation
515 in children with cerebral palsy. *Journal of Bone and Joint Surgery*. 2005;87(4):832.
- 516 45. Howard CB, McKibbin B, Williams LA, Mackie I. Factors affecting the incidence of hip
517 dislocation in cerebral palsy. *Journal of Bone and Joint Surgery - Series B*. 1985;67(4):530-2.
- 518 46. Hägglund G, Lauge-Pedersen H, Wagner P. Characteristics of children with hip displacement
519 in cerebral palsy. *BMC Musculoskelet Disord*. 2007;8:101.
- 520 47. Terjesen T. The natural history of hip development in cerebral palsy. *Dev Med Child Neurol*.
521 2012;54(10):951-7.
- 522 48. Hatstrup SJ, Cofield RH, Evidente VH, Sperling JW. Total shoulder arthroplasty for patients
523 with cerebral palsy. *Journal of Shoulder and Elbow Surgery*. 2007;16(5):e5-e9.
- 524 49. Tofts LJ, Elliott EJ, Munns C, Pacey V, Sillence DO. The differential diagnosis of children with
525 joint hypermobility: a review of the literature. *Pediatr Rheumatol Online J*. 2009;7:1-.
- 526 50. Monbaliu E, Ortibus E, Prinzie P, Dan B, De Cat J, De Cock P, et al. Can the Dyskinesia
527 Impairment Scale be used by inexperienced raters? A reliability study. *European journal of paediatric*
528 *neurology : EJPN : official journal of the European Paediatric Neurology Society*. 2013;17(3):238-47.
- 529 51. Vanmechelen I., Dan B., Feys H., Monbaliu E. Test-retest reliability of the Dyskinesia
530 Impairment Scale: Can dystonia and choreoathetosis be reliably measured over time in dyskinetic
531 cerebral palsy? *Dev Med Child Neurol*. 2019:under review.
- 532 52. Flamand VH, Massé-Alarie H, Schneider C. Psychometric evidence of spasticity measurement
533 tools in cerebral palsy children and adolescents: a systematic review. *J Rehabil Med*. 2013;45(1):14-
534 23.
- 535 53. Lebedowska MK, Gaebler-Spira D, Burns RS, Fisk JR. Biomechanic characteristics of patients
536 with spastic and dystonic hypertonia in cerebral palsy. *Archives of physical medicine and*
537 *rehabilitation*. 2004;85(6):875-80.
- 538 54. Rosenbaum P, Stewart D. The world health organization international classification of
539 functioning, disability, and health: a model to guide clinical thinking, practice and research in the
540 field of cerebral palsy. *Seminars in Pediatric Neurology*. 2004;11(1):5-10.

541

542

Table 1: Median and interquartile range of the presence and severity of spasticity, passive range of motion deviations, dystonia, and choreoathetosis; statistical comparisons and correlation coefficients between and within body regions

	Median (IQR) (%)	Median (IQR) (%)	Wilcoxon	r_s (95% CI), p-value	
					543
					544
	<u>Total UL</u>	<u>Total LL</u>			545
MAS presence	16.7 (8.3–41.7)	50.0 (30.0–80.0)	<0.001	0.34 (0.08–0.56), p=0.013	546
MAS severity	6.3 (2.1–13.5)	18.8 (8.8–30.0)	<0.001	0.38 (0.12–0.59), p=0.005	547
pROM-	8.3 (2.8–16.7)	27.5 (15.0–35.0)	<0.001	0.59 (0.38–0.74), p<0.001	548
pROM+	30.6 (22.2–36.1)	17.5 (10.0–22.5)	<0.001	0.44 (0.19–0.63), p=0.001	549
DIS-D	83.3 (62.5–94.8)	78.1 (52.1–87.5)	0.014	0.68 (0.50–0.80), p<0.001	550
DIS-CA	28.1 (14.6–53.1)	18.8 (8.8–41.3)	<0.001	0.68 (0.50–0.80), p<0.001	551
					548
	<u>UL proximal</u>	<u>UL distal</u>			549
MAS presence	25.0 (0.0–50.0)	12.5 (0.0–25.0)	0.001	0.47 (0.23–0.66), p<0.001	550
MAS severity	9.4 (0.0–25.0)	4.7 (0.0–9.4)	0.002	0.53 (0.30–0.70), p<0.001	551
pROM-	10.7 (3.6–17.9)	0.0 (0.0–0.0)	<0.001	0.32 (0.06–0.54), p=0.018	552
pROM+	21.4 (17.9–32.1)	50.0 (37.5–50.0)	<0.001	0.22 (-0.05–0.46), p=0.106	553
DIS-D	83.3 (58.3–95.8)	93.8 (66.7–97.9)	<0.001	0.64 (0.45–0.78), p<0.001	554
DIS-CA	31.3 (10.4–58.3)	28.1 (14.6–50.0)	0.870	0.76 (0.62–0.85), p<0.001	555
					552
	<u>LL proximal</u>	<u>LL distal</u>			553
MAS presence	33.3 (0.0–66.7)	75.0 (50.0–100.0)	<0.001	0.47 (0.23–0.66), p<0.001	554
MAS severity	10.4 (0.0–25.0)	25.0 (12.5–37.5)	<0.001	0.50 (0.27–0.68), p<0.001	555
pROM-	28.1 (18.8–40.6)	25.0 (0.0–25.0)	0.004	0.51 (0.28–0.69), p<0.001	556
pROM+	15.6 (9.4–21.9)	25.0 (0.0–37.5)	0.082	0.32 (0.06–0.54), p=0.020	557
DIS-D	68.8 (31.3–81.3)	83.3 (72.9–93.8)	<0.001	0.52 (0.29–0.69), p<0.001	558
DIS-CA	21.9 (4.2–37.5)	20.8 (4.2–43.8)	0.213	0.63 (0.43–0.77), p<0.001	559

MAS, Modified Ashworth Scale; pROM-, reduced passive range of motion; pROM+, increased passive range of motion (hypermobility); DIS-D, Dyskinesia Impairment Scale – Dystonia subscale; DIS-CA, Dyskinesia Impairment Scale – Choreoathetosis subscale; UL, upper limbs; LL, lower limbs; IQR, Interquartile Range; Wilcoxon, Wilcoxon signed-rank test; r_s, Spearman’s rho correlation coefficient; CI, confidence interval

Table 2: Absolute values (summed score out of the maximum score) and percentage values of the presence and severity of spasticity across different joint movements and muscle groups

		MAS presence (summed score/maximum score)	MAS presence (%)	MAS severity (summed score/maximum score)	MAS severity (%)	MAS severity (mode of MAS score, excluding 0 scores)	
LL	Ankle	Plantar flexion (soleus)	67/106	63.2	110/424	25.9	1.5
		Plantar flexion (gastrocnemius)	75/106	70.8	136.5/424	32.2	2
	Hamstrings	Popliteal angle	55/106	51.9	83.5/424	19.7	1
	Hip	Abduction (90°)	36/106	34.0	62/424	14.6	1.5
		Abduction (0°)	37/106	34.9	58.5/424	13.8	1.5
	UL	Elbow	Flexion (145°)	40/106	37.7	69.5/424	16.4
Extension (0°)			30/106	28.3	50/424	12.5	1
Forearm		Supination (85°)	33/106	31.1	48.5/424	11.4	1
		Pronation (90°)	6/106	5.7	9.5/424	2.2	1
Wrist		Dorsiflexion (70°)	24/106	22.6	36.5/424	8.6	2
		Palmar flexion (80°)	5/106	4.7	7/424	1.7	1

LL, lower limbs; UL, upper limbs; MAS, Modified Ashworth Scale; %, percentage;

560

561

Table 3: Percentage values of passive range of motion deviations across different joint movements; median and interquartile range of degrees of deviation

562

		Normal pROM	pROM -		pROM +		
		(degrees)	%	Median (IQR) (degrees)	%	Median (IQR) (degrees)	
LL	Ankle	Dorsiflexion	20°	10.8	-10 (-10--10)	28.8	15 (10-25)
		Plantarflexion	45°	32.1	-10 (-10-5)	13.2	10 (8.8-15.0)
	Knee	Flexion	145°	14.2	-15 (-35--10)	21.2	15 (5-15)
		Extension	5°	48.1	-15 (-25-5)	2.8	5 (5-5)
	Hip	Abduction	45°	28.3	-10 (-15-5)	23.6	10 (5-15)
		Adduction	30°	34.0	-10 (-15-10)	2.4	10 (5-10)
		Flexion	125°	39.6	-15 (-25-5)	12.3	5 (5-10)
		Extension	10°	19.8	-10 (-20-5)	15.1	10 (5-10)
		External rotation	45°	33.5	-15 (-25--10)	15.6	5 (5-15)
		Internal rotation	30°	2.8	-10 (-13.8-6.3)	44.8	30 (20-40)
UL	Elbow	Flexion	145°	13.7	-5 (-5-5)	36.3	5 (5-10)
		Extension	0°	5.7	-10 (-10-10)	34.4	10 (5-10)
	Shoulder	Flexion	180°	17.9	-30 (-45--20)	0.0	-
		Abduction	180°	17.5	-30 (-40--20)	0.9	20 (20-20)
		Adduction	30°	2.4	-5 (-6.3-5)	41.0	15 (10-20)
		External rotation	80°	1.4	-30 (-35--20)	47.2	10 (10-10)
		Internal rotation	70°	35.8	-20 (-30-10)	6.6	10 (8.8-20)
		Dorsiflexion	70°	6.6	-15 (-42.5-10)	41.0	20 (10-20)
	Wrist	Palmar flexion	80°	3.3	-10 (-12.5-10)	50.9	20 (10-25)

LL, lower limbs; UL, upper limbs; pROM-, limited passive range of motion; pROM+, increased passive range of motion (hypermobility); %, percentage, IQR, interquartile range

Table 4: Correlation coefficients of dystonia and choreoathetosis with presence of spasticity, severity of spasticity, and passive range of motion deviations

		MAS presence r_s (95% CI); p-value	MAS severity r_s (95% CI); p-value	pROM- r_s (95% CI); p-value	pROM+ r_s (95% CI); p-value	
DIS-D	Total	0.41 (0.16–0.61); p=0.002	0.44 (0.19–0.63); p=0.001	0.47 (0.23–0.66); p<0.001	-0.09 (-0.35–0.18); p=0.538	
	UL	Proximal	0.50 (0.27–0.68); p<0.001	0.54 (0.32–0.71); p<0.001	0.37 (0.11–0.58); p=0.007	-0.06 (-0.33–0.21); p=0.674
		Distal	0.17 (-0.11–0.42); p=0.213	0.18 (-0.09–0.43); p=0.210	0.35 (0.09–0.57); p=0.011	0.03 (-0.24–0.30); p=0.853
		Total	0.33 (0.07–0.55); p=0.016	0.41 (0.16–0.61); p=0.002	0.31 (0.04–0.54); p=0.025	0.05 (-0.22–0.32); p=0.730
	LL	Proximal	0.37 (0.11–0.58); p=0.007	0.45 (0.21–0.64); p=0.001	0.35 (0.09–0.57); p=0.010	-0.05 (-0.17–0.37); p=0.762
		Distal	0.18 (-0.09–0.43); p=0.191	0.18 (-0.09–0.43); p=0.207	0.15 (-0.13–0.40); p=0.285	0.11 (-0.05–0.46); p=0.439
Total		0.26 (-0.01–0.50); p=0.064	0.22 (-0.05–0.46); p=0.121	0.14 (-0.14–0.40); p=0.320	0.07 (-0.20–0.30); p=0.631	
DIS-CA	UL	Proximal	0.35 (0.09–0.57); p=0.010	0.35 (0.09–0.57); p=0.010	0.08 (-0.19–0.34); p=0.589	0.11 (-0.17–0.37); p=0.449
		Distal	-0.03 (-0.30–0.24); p=0.839	-0.07 (-0.33–0.20); p=0.605	0.05 (-0.22–0.32); p=0.746	0.04 (-0.23–0.31); p=0.768
		Total	0.15 (-0.13–0.40); p=0.294	0.14 (-0.14–0.40); p=0.320	-0.25 (-0.49–0.02); p=0.077	0.44 (0.19–0.63); p=0.001
	LL	Proximal	0.26 (-0.01–0.50); p=0.062	0.26 (-0.01–0.50); p=0.063	-0.04 (-0.31–0.23); p=0.806	0.35 (0.09–0.57); p=0.012
		Distal	0.05 (-0.22–0.32); p=0.719	0.01 (-0.26–0.28); p=0.960	-0.26 (-0.50–0.01); p=0.058	0.18 (-0.09–0.43); p=0.202
		Total				

DIS-D, Dyskinesia Impairment Scale – Dystonia subscale; DIS-CA, Dyskinesia Impairment Scale – Choreoathetosis subscale; UL, upper limbs; LL, lower limbs; MAS, Modified Ashworth Scale; pROM-, limited passive range of motion; pROM+, increased passive range of motion (hypermobility); r_s, Spearman's rho correlation coefficient; CI, confidence interval

Table 5: Correlation coefficients of the Gross Motor Functional Classification System with the presence of spasticity, severity of spasticity, passive range of motion deviations, dystonia, and choreoathetosis of the lower limbs; and correlation coefficients between the Manual Ability Classification System with the presence of spasticity, severity of spasticity, passive range of motion deviations, dystonia, and choreoathetosis of the upper limbs

	GMFCS		MACS	
	<i>r_s</i> (95% CI)	<i>p</i> value	<i>r_s</i> (95% CI)	<i>p</i> value
MAS presence	0.32 (0.06–0.54)	0.018	0.40 (0.15–0.60)	0.003
MAS severity	0.42 (0.17–0.62)	0.002	0.44 (0.19–0.63)	0.001
pROM-	0.51 (0.28–0.69)	<0.001	0.34 (0.08–0.56)	0.014
pROM+	-0.23 (-0.47–0.04)	0.099	-0.10 (-0.36–0.18)	0.490
DIS-D	0.65 (0.46–0.78)	<0.001	0.78 (0.65–0.87)	<0.001
DIS-CA	0.07 (-0.20–0.33)	0.632	0.31 (0.04–0.54)	0.027

GMFCS, Gross Motor Function Classification System; MACS, Manual Ability Classification System; MAS, Modified Ashworth Scale; pROM-, reduced passive range of motion; pROM+, increased passive range of motion (hypermobility); DIS-D, Dyskinesia Impairment Scale – Dystonia subscale; DIS-CA, Dyskinesia Impairment Scale – Choreoathetosis subscale; *r_s*, Spearman's rho correlation coefficient; CI, confidence interval